ReviewTherapeutic advances in medical oncology2025
Early and hereditary breast cancer: advances in risk stratification and imaging approaches.
Review in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
- Hematologic Glyco-Signatures: Emerging Blood-Based Sugar Codes Linked to Hyper-Aggressive Breast Cancer.Breast cancer (Dove Medical Press) · 2026Review
- Lung cancer in non-smoking women (LCINSW): from risk factors to precision therapy.Cancer metastasis reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains a leading global health challenge, characterized by significant heterogeneity that complicates its detection, diagnosis, and management. The integration of imaging biomarkers and radiomics into clinical workflows has revolutionized early detection, risk stratification, and personalized treatment strategies. Established modalities, such as mammography and magnetic resonance imaging, in conjunction with biomarkers like hormone receptor status, continue to play a pivotal role in guiding therapeutic decisions. Simultaneously, advancements in radiomics and artificial intelligence (AI) have enabled the extraction and analysis of high-dimensional imaging data, offering novel insights into tumor biology and predicting treatment outcomes. This review explores the synergy of imaging biomarkers, radiomics, and AI, emphasizing their potential to transform BC care through enhanced precision and optimized patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.